Spinal muscular atrophy (SMA) is a devastating condition which, in the most severe cases, leaves babies with a life expectancy of rarely more than two years. Spinraza (also known as nusinersen) has been developed by pharmaceutical company Biogen and is the first treatment for people with SMA. It was approved by the European Medicines Agency (EMA) in June 2017. Clinical trials showed the treatment led to a significant improvement in children’s motor function, allowing them to achieve, or maintain, physical milestones that they would never reach without treatment, and to survive longer than expected considering the typical course of the condition. Some children who would never have sat independently have been able to and some have also been able to crawl and even walk.
Information and guidance
NICE, NHS England and NHS Improvement have taken advice from clinical experts and consulted with patient advisory groups Muscular Dystrophy UK, Treat SMA, and SMA UK to produce a series of question-and-answer documents relating to Spinraza.
Spinraza update May 2021
NICE has completed its review of the eligibility criteria for the Spinraza managed access agreement (MAA) in relation to non-ambulant people with SMA Type 3.
Following NICE’s review of data they’ve collected as part of the Managed Access Agreement (MAA) for Spinraza, more people with spinal muscular atrophy (SMA) are now eligible for access to it. Patient groups – MDUK, SMA UK and TreatSMA – have been working since 2019 with clinicians and others so that people with SMA Type 3, who are unable to walk, can access nusinersen too.
NICE concluded in its review that it was appropriate to extend the clinical eligibility criteria to allow access to nusinersen for those with SMA Type 3, who aren’t able to walk. The review has also removed the rule that meant those who lost the ability to walk after 12 months of treatment would no longer be eligible for further treatment.
The review, which involved Biogen, patient groups, clinicians, SMA REACH UK and NHS England and NHS Improvement, assessed whether new evidence had become available to support a change in the MAA treatment eligibility criteria. Specifically, it looked at whether people with SMA Type 3, who are unable to walk, could benefit from nusinersen and so should be included in the MAA.
NHS England is developing its service capacity to deliver nusinersen to this wider group and, as COVID-19 restrictions ease, they will be able to expand this capacity further. Where there are already established services, some people will be able to access to the treatment immediately.
The MAA document has been updated to reflect the changes and you can find these here.
You can find out more about the review and the accompanying documentation on the NICE website.
Questions and answers
Spinal muscular atrophy (SMA) is a rare inherited neuromuscular condition where the loss of motor neurons cause muscles to waste away, resulting in progressive muscular weakness and loss of movement. It can affect crawling and walking ability, arm, hand, head and neck movement, breathing and swallowing.
There are four types of SMA:
SMA Type 1: Symptoms appear within the first few months of life, sometimes before birth. Children are never able to sit unaided and rarely survive their second birthday without treatment.
SMA Type 2: Symptoms usually appear between 7-18 months of age. Children are never able to stand unaided. Although the condition may shorten life expectancy, improvements in care standards mean that the majority of people can live long and fulfilling lives.
SMA Type 3: Symptoms appear after 18 months of age. Children are able to stand and walk, but will become less able to walk over time. Life expectancy is normal and most people can live long independent lives.
SMA Type 4 (also known as adult onset SMA): Symptoms appear in adulthood. It is not a life-threatening condition.
There are estimated to be up to 1,300 children and adults living with SMA in the UK. In 2015, approximately 78 babies were born with SMA and, of these, 43 had SMA Type 1 – the most aggressive type of SMA.
There is more information about the condition on the following websites: Muscular Dystrophy UK, SMA UK.
Spinraza is the first treatment for SMA. Developed by pharmaceutical company Biogen, clinical trials have shown significant improvement in children’s motor function; for the first time, we have seen children with SMA Type 1 crawl and even walk. Families of children who have received the drug often report noticeable improvements from the start of treatment. The drug proved so effective in clinical trials with children with SMA Type 1 that in August 2016 they were stopped early so all the children could access the drug.
The drug also has promise for the other types of SMA; motor function for children with SMA Type 2 and 3 was significantly improved in trials. In April 2019, a three-year study of 28 children aged between two and 15, which was published in the scientific journal Neurology, highlighted meaningful improvements that extended over time. Some of these improvements were remarkably different to the natural progression of the condition when left untreated. In particular, a two-year-old child with SMA Type 2 gained the ability to walk independently after receiving Spinraza, while two children with SMA Type 3 who had lost the ability to walk before taking the drug regained it during the study.
A clinical trial is ongoing in pre-symptomatic infants with genetically-diagnosed SMA, who are considered to be likely to develop SMA Type 1 or Type 2. As of July 2019, children treated with Spinraza continue to achieve motor milestones that are unprecedented in the natural history of the condition, including 100 per cent of children sitting without support and 88 per cent walking independently.
While the drug was highly effective in most treated children, there were some who did not respond to the treatment. Some patients may also be too weak to receive the intrathecal injection via a lumbar puncture.
Clinical trials have also highlighted that the greatest benefit is observed in patients who start treatment earlier.
England, Wales and Northern Ireland: Biogen set up an Expanded Access Programme (EAP) in 2016 following successful clinical trials. This provides the drug for free while assessments into its provision are made. However, on 22 August 2018 it was announced that the scheme would close to new entrants in November 2018.
In July 2019, NICE, Biogen and NHS England came to an arrangement on a Managed Access Agreement, which allows some children and adults with SMA Types 1, 2 and 3 to access the treatment in England. However, patients have to meet a series of criteria, including:
Paediatric patients who have walked previously but lost ambulation will only be eligible if they lost the ability to walk in the last 12 months. They also need to regain ambulation within 12 months of starting treatment to continue receiving treatment.
Some patients with scoliosis and contractures may not be able to receive treatment if an intrathecal injection is not feasible.
The full criteria can be read here.
On 24 July 2019, NICE published its final guidance. This can be read here.
Rollout of treatment is expected shortly. Patients who are most severely affected will be prioritised.
Scotland: The Scottish Medicines Consortium (SMC), the Scottish equivalent of NICE, approved Spinraza for use on the NHS for children with SMA Type 1 in May, replacing the EAP.
In February 2019, it was announced that the treatment would be made available for people with SMA Type 2 and Type 3 through a new ultra-orphan pathway introduced by the government. In July 2019, the SMC said that Spinraza would be prescribed for children and adults with SMA Types 2 and 3 through this pathway for a period of up to three years while further evidence on its effectiveness is generated. Some children have already received treatment, having been considered on a case-by-case basis.
Spinraza was appraised by NICE through its Single Technology Appraisal (STA) process, which is traditionally used for treatments for more common conditions. This process started in January 2018, meaning patients have faced a lengthy 16-month wait up until this point.
NICE gave the drug a negative opinion in an appraisal consultation document published on 14 August 2018. It had been due to make a final recommendation in November 2018. In May 2019, it announced it would approve Spinraza for people with SMA Types 1, 2 and 3, after coming to an agreement with NHS England and Biogen.
Part of the delay has been because of the unsuitability of NICE’s appraisal routes. There are only two: the STA route, through which Spinraza would typically be too expensive; and a specialist treatment route, unsuitable for Spinraza as it can benefit too many people. This is not the first time that a treatment to help people with muscle-wasting conditions has been heavily delayed. We need to see an overhaul of these routes to ensure rare disease drugs aren’t held up in future.
See the timeline at the end of this page for further details.
A managed access agreement (MAA) is an interim scheme that will allow patients with SMA to access Spinraza, so that data can be gathered on the treatment’s effectiveness while ensuring access. The aim of an MAA is to temporarily deliver a treatment through the NHS while a longer-term agreement to provide it is agreed. The length of time a MAA is implemented can vary, but three to five years is typical.
Wales and Northern Ireland usually follow NICE guidance. We have been seeking assurances that they will be doing so in this case. This will mean that the treatment can be accessed UK-wide.
Before individual European countries examine a treatment, they are first of all licensed by the European Medicines Agency (EMA). Spinraza was recommended in April 2017 by the EMA to be licensed as a treatment for SMA Types 1, 2, 3, 4. In June 2017, the European Commission finalised the recommendation.
Spinraza is available for children and some adults with all types of SMA in 24 European countries. Negotiations are under way in other countries. More widely, Spinraza was approved in the United States in December 2016, and has gained additional approvals in Korea, Canada, Japan, Brazil and Australia since then.
Patients with SMA lack a protein called ‘survival motor neuron’ (SMN) protein, which is essential for motor neurons to survive and function normally. The SMN protein is made from two genes, SMN1 and SMN2. Patients with SMA lack the SMN1 gene but have the SMN2 gene, which mostly produces a short SMN protein that does not work as well as a full-length protein.
Spinraza is a synthetic anti-sense oligonucleotide (a type of genetic material) that enables the SMN2 gene to produce full length protein, which is able to work normally. This replaces the missing protein, thereby relieving the symptoms of the disease.
Spinraza is administered through an injection into the spinal canal in an established procedure known as an intrathecal injection. This delivers medication through the lower back via a lumbar puncture and directly into the central nervous system. This procedure is performed under the direction of healthcare providers experienced in administering lumbar punctures and requires special precautions – either sedation or general anaesthetic.
The list price of Spinraza is £75,000 per vial (excluding VAT; British National Formulary, accessed June 2018). This would mean the total annual treatment cost is £450,000 for the first year and £225,000 for subsequent years.
Biogen only presented evidence for SMA Types 1, 2 and 3, and the consensus is that Spinraza has greatest impact on people with those types. NICE can provide more information on its website.
Spinraza is the only treatment that has been approved for NHS use. However, a gene therapy called Zolgensma is due to be assessed by NICE through its HST route for use in the NHS for infants with SMA Type 1.
Zolgensma, which has shown to be effective in clinical trials, has been approved by the FDA, but as of July 2019 had yet to receive EMA approval. As such, the treatment is not currently available in the UK, or elsewhere in Europe.
You may come across different acronyms when hearing people talk about Spinraza. Below is a guide to what these mean.
AAP: Accelerated Access Programme. A government scheme to fast-track breakthrough treatments announced in November 2017. We are waiting to hear if rare disease drugs will be eligible for it.
EAP: Expanded Access Programme. A special scheme currently providing access to Spinraza for those with SMA Type 1 from the pharmaceutical company Biogen. This was closed on 1 November 2018.
EMA: European Medicines Agency. Pharmaceutical treatments typically need to get a licence for marketing a drug from the EMA before they are assessed by NICE. The EMA approved Spinraza in 2017.
FDA: The U.S. Food and Drug Administration, which decides on treatments in the USA
HST: Highly Specialised Technology route. One of the two routes, along with STA, through which NICE assess treatments in England.
MAA: Managed Access Agreement. This is an agreement to provide treatment on the NHS while more data is gathered on its efficacy, and we want to see one put in place for Spinraza in England, Wales and Northern Ireland.
NICE: National Institute for Health and Care Excellence. NICE is in charge of recommending whether treatments should be funded on the NHS.
PACE: Patient and Clinical Experts. A special meeting held by the SMC to garner views.
SMA: Spinal muscular atrophy.
SMC: Scottish Medicines Consortium. The SMC is in charge of recommending treatments for provision on the NHS in Scotland.
STA: Single Technology Appraisal route. The main route through which NICE assesses treatments in England, including Spinraza.
August 2016: The drug proves so effective in clinical trials with children with SMA Type 1 that they are stopped early so that all the children can access the drug. Biogen then opens its Expanded Access Programme (EAP) for Spinraza, offering the drug free to all children with SMA Type 1 who showed signs of SMA before six months of age in the UK.
21 April 2017: The drug is recommended by the European Medicines Agency (EMA) to be licensed as a treatment for SMA Types 1, 2, 3, 4.
1 June 2017: The European Commission finalises the recommendation by the European Medicines Agency (EMA).
August 2017: NHS England agrees to support delivery costs for Spinraza, but only for children with two copies of the SMN2 gene (around 80% of children), as these were the only children involved in the clinical trials.
November 2017: The Department of Health announces a new, fast-track route into the NHS for ‘breakthrough’ medicines and technologies, known as the Accelerated Access Pathway (AAP). Five drugs a year will benefit – but no criteria is given and the scope of the scheme is unclear.
November 2017: The Scottish Medicines Consortium (SMC) starts its appraisal of Spinraza.
January 2018: NICE announces it will begin its appraisal of Spinraza for SMA Types 1, 2, 3 and 4 through its Single Technology Appraisal (STA) route. Discussions of an interim scheme, known as a managed access agreement (MAA), also get under way between manufacturers Biogen, NHS England, and NICE.
13 March 2018: Families and charities make submissions and give evidence on the benefits of Spinraza at a Patient and Clinical Experts (PACE) meeting held by the Scottish Medicines Consortium (SMC).
3 April 2018: The Scottish Medicines Consortium (SMC) holds a second meeting for final submissions from charities and families on why Spinraza should be approved in Scotland.
7 May 2018: The Scottish Medicines Consortium (SMC)’s appraisal of Spinraza is published. It recommends it for use on the NHS in Scotland for children with Type 1 SMA – but not Types 2 and 3.
14 August 2018: NICE publishes its appraisal consultation document for Spinraza, setting out provisional recommendations for not approving the treatment for use on the NHS in England. This was originally expected to be released in June.
22 August 2018: Biogen announces it will be stopping the Expanded Access Programme from 1 November for all babies who are diagnosed after this date. Biogen says babies and children currently on this scheme will not be affected.
8 October 2018: The Scottish Government launches the ultra-orphan pathway for rare treatments.
1 November 2018: Biogen’s Expanded Access Programme is closed to new patients.
13 February 2019: Announcement is made that Spinraza is due to be made available on the NHS in Scotland for children and adults with SMA Types 1, 2 and 3, having been assessed through an ultra-orphan pathway.
6 March 2019: NICE holds a third committee meeting to discuss Spinraza.
8 May 2019: A fourth NICE committee meeting, held in private, is held to discuss Spinraza.
15 May 2019: NICE and NHS England announce they have negotiated a deal with Biogen to make Spinraza available in the NHS for children and adults with SMA Types 1, 2 and 3, through a managed access agreement.
3 June 2019: NICE releases its final appraisal document and MAA. Patient groups, including Muscular Dystrophy UK, seek clarification around some of the criteria in the MAA around eligibility.
14 June 2019: Muscular Dystrophy UK co-signs a letter along with leading clinicians, SMA UK and Treat SMA to NICE and NHS England, asking for amendments to be made to the MAA criteria.
20 June 2019: NICE confirms it has received one appeal against the draft MAA.
3 July 2019: NICE announces amendments to the managed access agreement (MAA) for Spinraza for people with SMA Types 1, 2 and 3, following strong representation from clinicians and the patient community.
24 July 2019: NICE publishes its final guidance on Spinraza, which will be made available in the NHS for patients with SMA Types 1, 2 and 3, providing they meet certain criteria.